The global market for novel weight-loss drugs like Novo Nordisk A/S's Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.
An advisory panel to the FDA unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA twice rejected the implant.
Washington's revolving door kept spinning this week as the DEA's recently departed second-in-command returned for a new stint with the high-powered consulting firm where he previously advised Purdue Pharma and a drug distributor.